Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Spatial transcriptomics identifies a suppressive, T-cell excluded tumor microenvironment in extramedullary myeloma.

Blood advances·2026

Same author

Real-world application of the International Myeloma Society (IMS)/International Myeloma Working Group (IMWG) consensus on genomic staging for high-risk multiple myeloma: A report from the Australia and New Zealand Myeloma and Related Diseases Registry.

British journal of haematology·2026

Same author

Valganciclovir for CMV Prophylaxis After PTCy-Based Allogeneic Hematopoietic Cell Transplantation.

Transplantation and cellular therapy·2026

Same author

A Critical Review of Clinical Factors and Tools for Predicting Chimeric Antigen Receptor T-Cell Toxicities.

Transplantation and cellular therapy·2026

Same author

CD34+ Chimerism and Flow Cytometry Measurable Residual Disease are Independent Predictors of Relapse After Allogeneic Stem Cell Transplantation for AML.

Transplantation and cellular therapy·2026

Same author

HAT-PCR is non-inferior to NGS when quantifying measurable residual disease for myeloma.

British journal of haematology·2026

Search research articles

Related Experiment Video

Updated: Feb 17, 2026

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

Published on: June 8, 2019

Circulating tumour DNA analysis in multiple myeloma

Sridurga Mithraprabhu¹, Andrew Spencer¹

¹Andrew Spencer: Australian Centre for Blood Diseases, Monash University, Malignant Haematology & Stem Cell Transplantation, Alfred Hospital and Department of Clinical Haematology, Monash University, Melbourne, Australia.

|December 7, 2017

Summary

No abstract available in PubMed .

Keywords:

cell-free DNA circulating tumour DNA multiple myeloma mutations therapeutic monitoring

More Related Videos

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma

Published on: April 15, 2022

Target Cell Pre-enrichment and Whole Genome Amplification for Single Cell Downstream Characterization

Target Cell Pre-enrichment and Whole Genome Amplification for Single Cell Downstream Characterization

Published on: May 15, 2018

Related Experiment Videos

Last Updated: Feb 17, 2026

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

Published on: June 8, 2019

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma

Published on: April 15, 2022

Target Cell Pre-enrichment and Whole Genome Amplification for Single Cell Downstream Characterization

Target Cell Pre-enrichment and Whole Genome Amplification for Single Cell Downstream Characterization

Published on: May 15, 2018